Compare XPOF & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | IVVD |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.6M | 212.6M |
| IPO Year | 2021 | 2021 |
| Metric | XPOF | IVVD |
|---|---|---|
| Price | $4.14 | $0.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $5.60 | ★ $10.00 |
| AVG Volume (30 Days) | 717.8K | ★ 4.6M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.24 | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | $11,092,000.00 | ★ $53,426,000.00 |
| Revenue This Year | N/A | $12.40 |
| Revenue Next Year | $5.32 | $44.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $3.57 | $0.53 |
| 52 Week High | $9.25 | $3.07 |
| Indicator | XPOF | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 36.58 | 37.35 |
| Support Level | $3.83 | $0.60 |
| Resistance Level | $6.15 | $1.02 |
| Average True Range (ATR) | 0.25 | 0.06 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 4.91 | 9.53 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.